新复方党参片防治高原脱习服的临床疗效

目的：研究新复方党参片对高原脱习服的防治作用。方法：驻守海拔5200 m一年的男性青年官兵43人随机分为新复方党参片组（28人）和对照组（15人）,采用单盲试验法。自返回驻地（海拔1400 m）前5 d开始分别口服新复方党参片和安慰剂片,直至返回驻地的第7天停药,共服药12 d。返回驻地的第2、4、6天,按高原脱习服症状调查表随访受试者的脱习服症状并进行症状分度评分。返回驻地的第7天,检测受试者的用力肺活量（FVC）、1秒钟用力呼气量（FEV1.0）、一秒率（FEV1.0/FVC,FEV1%）、最大呼气中期流速（FEF25%-75%）、呼气峰流速（PEF）、最大通气量（MVV）、左右手交叉敲击动作频率总次数（Ttis）和数字记忆广度顺背数测验得分（Sum）。结果：与对照组比较,返回驻地的第2、4、6天,新复方党参片组高原脱习服症状显著减轻（P〈0.01）;新复方党参片组与对照组的高原脱习服症状程度分度分布不同（P〈0.01）,新复方党参片组症状较轻的（基本无反应、轻度反应）占比重较大,而对照组中症状较重的（中度反应、重度反应）占比重较大;新复方党参片组高原脱习服发生率明显降低;新复方党参片组的FVC、FEV1.0、PEF、MVV均显著升高（P〈0.05,P〈0.01）,FEV1%和FEF25%-75%无统计学差异;新复方党参片组Ttis、Ctis显著增加（P〈0.05,P〈0.01）,平均时间（Atime）显著减少（P〈0.05）,错误次数（Etis）和Sum差异不显著。结论：新复方党参片能减轻高原脱习服的程度,减轻高原脱习服的症状,降低高原脱习服发生率;并能显著改善受试者的肺通气功能和手指运动能力,具有较好的防治高原脱习服的作用。

Therapeutic effects of the new compound codonopsis tablets against deacclimatization to high altitude

AIM: To study the therapeutic effects of new compound codonopsis tablets against deacclima-tization to high altitude. METHODS: Forty-three male soldiers stayed at 5200 m altitude for one year were randomly divided into two groups: control group (15 men) and treatment group (28 men). Single blind trial was used in this study. Five days before they return to plain (1400 m), they were taken placebo and new compound codonopsis tablets respectively until they arrived in for one week. The questionnaire of symptoms of deacclimatization to high altitude was used on the 2nd, 4th, 6th day after they returned to 1400 m altitude. On the 7th day after returning to 1400 m, FVC (forced vital capacity), FEV1. 0 (forced expired volume in one second), FEV1% (FEV1. 0/FVC), FEF25% - 75%, PEF (peak expiratory flow) and MVV (maximal voluntary ventilation) were determined with a spirometer (SriroAnalyzer ST-75) , total frequency of hands cross movement and memory of order numbers were tested with a neurosychological monitoring system (DDX-200). RESULTS: Compared with control, symptoms of deacclimatization to high altitude of treatment group were reduced significantly on the 2nd, 4th, and 6th day after returning to 1400 m (P < 0.01) . The degree of symptoms of deacclimatizating to high altitude in treatment group was distinctly different from that of control (P < 0.01). The proportion of slight symptoms in treatment group was high, and that of relative serious symptoms was low. Compared with control, FVC, FEV1.0, PEF and MVV of treatment group were increased significantly (P < 0.05, P < 0.01). Ttis, Ctis in treatment group were increased (P < 0.05), Atime was decreased markedly (P < 0.05). There was no statistically significant difference in Etis and Sum between the two groups. CONCLUSION: New compound codonopsis tablets could decrease the incidence of deacclimatization to high altitude, mitigate the symptoms of deacclimatization to high altitude, improve the breathing function and fingers movement function. New compound codonopsis tablets have a significant effect on prevention and treatment of deacclimatization to high altitude.